Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference34 articles.
1. Throckmorton DC. Presentation: FDA Perspective on Abuse-Deterrent Opioid Development. 2017. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM545923.pdf . Accessed 20 Dec 2017.
2. Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86(12):1601–6.
3. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–51. https://doi.org/10.1176/appi.ajp.2013.12060782 .
4. Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–96. https://doi.org/10.1016/j.pain.2013.05.053 .
5. U.S. Food and Drug Administration. Abuse-Deterrent Opioids. 2017. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm . Accessed Dec 18 2017.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献